T. Yeo

Mixed Alkyl/Aryl Phosphonates Identify Metabolic Serine Hydrolases as Antimalarial Targets

The paper identifies mixed alkyl/aryl phosphonates as anti-malarial compounds that inhibit serine hydrolases with low resistance potential.

Quinoxaline-Based Anti-Schistosomal Compounds Have Potent Anti-Malarial Activity

This study identifies quinoxaline-based anti-schistosomal compounds with potent anti-malarial activity against Plasmodium falciparum, including resistance mechanisms involving pfqrp1 and pfatp2.

Covalent macrocyclic proteasome inhibitors mitigate resistance in Plasmodium falciparum

This paper develops covalent macrocyclic proteasome inhibitors for Plasmodium falciparum that show reduced resistance compared to reversible inhibitors.

Generation of a mutator parasite to drive resistome discovery in Plasmodium falciparum

This study creates a mutator parasite of Plasmodium falciparum to enhance drug resistance discovery by increasing mutation rates and identifying resistance mechanisms.

Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183

This paper characterizes MMV693183, a novel antimalarial compound targeting acetyl-CoA synthetase, showing in vitro and in vivo efficacy against Plasmodium species and transmission blocking.

P. falciparum K13 mutations present varying degrees of artemisinin resistance and reduced fitness in African parasites

This study examines K13 mutations in Plasmodium falciparum, showing varying degrees of artemisinin resistance and fitness costs in African parasites, while finding no significant impact on ART susceptibility in Southeast Asian strains.

Plasmodium falciparum K13 mutations in Africa and Asia present varying degrees of artemisinin resistance and an elevated fitness cost in African parasites

The antimalarial natural product salinipostin A identifies essential α/β serine hydrolases involved in lipid metabolism in P. falciparum parasites

The study identifies essential α/β serine hydrolases in P. falciparum as targets of the antimalarial Salinipostin A, which disrupt lipid metabolism and inhibit parasite growth.